Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

ONCO Prime is a cutting-edge drug discovery platform identifying novel synthetic lethal targets using patient-derived primary cell cultures. Initial data have identified potentially novel drug targets in KRAS-mutant colorectal cancer (CRC), and the platform has broad applicability across…